AnaptysBio Files 8-K on Nov 10, 2025

Ticker: ANAB · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1370053

Anaptysbio, Inc 8-K Filing Summary
FieldDetail
CompanyAnaptysbio, Inc (ANAB)
Form Type8-K
Filed DateNov 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

Related Tickers: ANAB

TL;DR

ANAB filed an 8-K on 11/10/25 - check for Reg FD, other events, and financials.

AI Summary

AnaptysBio, Inc. filed an 8-K on November 10, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. Specific details regarding the nature of these events or financial figures are not provided in the excerpt.

Why It Matters

This 8-K filing indicates that AnaptysBio, Inc. has made disclosures or reported on significant events on November 10, 2025, which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and disclosures, with no immediate indication of significant negative news or financial distress.

Key Players & Entities

  • ANAPTYSBIO, INC (company) — Registrant
  • November 10, 2025 (date) — Date of Report and Earliest Event
  • Delaware (jurisdiction) — State of Incorporation
  • 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (address) — Principal Executive Offices
  • 858-362-6295 (phone_number) — Registrant's Telephone Number

FAQ

What specific events are being disclosed under Regulation FD?

The provided excerpt does not specify the details of the Regulation FD disclosures made on November 10, 2025.

What 'Other Events' are reported in this 8-K filing?

The excerpt does not provide information on the specific 'Other Events' reported by AnaptysBio, Inc.

Are there any significant financial statements or exhibits included with this filing?

The filing indicates that 'Financial Statements and Exhibits' are part of the report, but the excerpt does not detail their content.

When was AnaptysBio, Inc. incorporated and in which state?

AnaptysBio, Inc. was incorporated in Delaware.

What is the principal executive office address and phone number for AnaptysBio, Inc.?

The principal executive office is located at 10770 Wateridge Circle, Suite 210, San Diego, CA 92121, and the phone number is (858) 362-6295.

Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-11-10 09:10:20

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke

Filing Documents

01. Regulation FD

Item 7.01. Regulation FD. On November 10, 2025, AnaptysBio, Inc. ("AnaptysBio") updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

01. Other Items

Item 8.01. Other Items On November 10, 2025, AnaptysBio issued a press release regarding top-line Phase 2 data in ulcerative colitis with rosnilimab. A copy of the press release is filed herewith as Exhibit 99.2.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 Anaptys Corporate Presentation November 2025. 99.2 AnaptysBio, Inc. Press Release, dated November 10, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: November 10, 2025 By: /s/Dennis Mulroy Name: Dennis Mulroy Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.